PEMPHIGUS VULGARIS, CURRENT STATUS AND PROSPECTS
DOI:
https://doi.org/10.52340/jecm.2023.03.14Keywords:
Pemphigus vulgaris, treatment, side effectsAbstract
Pemphigus vulgaris refers to a group of autoimmune blistering diseases of skin and mucous membranes. Like other autoimmune diseases, what causes the pemphigus diseases is not really understood. Researchers believe genetic and environmental factors may influence the disease. The article presents various methods of treatment of pemphigus vulgaris, with its pros and cons. It is important that each method and dosage are properly chosen to achieve a positive therapeutic effect on the background of minimal side effects.
Downloads
References
Kaegi C, Wuest B, Schreiner J, et al. Systematic review of safety and efficacy of rituximab in treating immune-mediated disorders. Front Immunol. 2019;10:1990. doi:10.3389/fimmu.2019.01990
Cheesman S. Introduction of biosimilar rituximab: a hospital perspective. Hemasphere. 2020;5(1):e515.
Brochado MJF, Nascimento DF, Campos W, Deghaide NHS, Donadi EA, Roselino AM. Differential HLA class I and class II associations in pemphigus foliaceus and pemphigus vulgaris patients from a prevalent Southeastern Brazilian region. J Autoimmun. 2016;72:19–24. doi:10.1016/j. jaut.2016.04.007
Walsh P, Brochado MJF, Vernal S, et al. Relationship between pemphigus and American tegumentary leishmaniasis: insights from serological and genetic profiles. Trans R Soc Trop Med Hyg. 2017;111(8):345–53.
Salathiel AM, Brochado MJF, Kim O, Deghaide NHS, Donadi EA, Roselino AM. Family study of monozygotic twins affected by pemphigus vulgaris. Hum Immunol. 2016;77(7):600–604.
Fania L, Moro F, De Paolis E, et al. Pemphigus vulgaris in two pairs of siblings from two unrelated Italian families: human leukocyte antigen genotypes, ST18 mutation and immunological profile. J Dermatol. 2021;48(2):211–214. doi:10.1111/1346-8138.15656
Malik AM, Tupchong S, Huang S, Are A, Hsu S, Motaparthi K. An updated review of pemphigus diseases. Medicina. 2021;57(10):1080. doi:10.3390/medicina57101080
Kridin K. Pemphigus group: overview, epidemiology, mortality, and comorbidities. Immunol Res. 2018;66(2):255–270. doi:10.1007/s12026-018-8986-7
Didona D, Maglie R, Eming R, Hertl M. Pemphigus: current and Future Therapeutic Strategies. Front Immunol. 2019;10:1418. doi:10.3389/ fimmu.2019.01418
Yuan H, Pan M, Chen H, Mao X. Immunotherapy for Pemphigus: Present and Future. Front Med (Lausanne). 2022 Jun 15; 9:901239. Doi: 10.3389/fmed.2022.901239
Schmidt E, Zillikens D. Modern diagnosis of autoimmune blistering skin diseases. Autoimmun Rev. 2010;10(2):84–89. PMID: 20713186.
Pohla Gubo G, Hintner H. Direct and indirect immunofluorescence for the diagnosis of bullous autoimmune diseases. Dermatol Clin. 2011;29(3):365–372, vii. PMID: 21605801.
Venugopal SS, Murrell DF. Diagnosis and clinical features of pemphigus vulgaris. Dermatol Clin. 2011;29(3):373–380. PMID: 21605802
Aimee S. Payne, John R. Stanley. Pemphigus. Fitzpatrick’s Dermatology in general medicine. Section 8. Chapter 54. P 586-599.
Tran KD, Wolverton JE, Soter NA. Methotrexate in the treatment of pemphigus vulgaris: experience in 23 patients. Br J Dermatol. 2013 Oct;169(4):916-21. doi: 10.1111/bjd.12474. PMID: 23772610.
Baum S, Greenberger S, Samuelov L, Solomon M, Lyakhovitsky A, Trau H, Barzilai A. Methotrexate is an effective and safe adjuvant therapy for pemphigus vulgaris. Eur J Dermatol. 2012 Jan-Feb;22(1):83-7. doi: 10.1684/ejd.2011.1611. PMID: 22266247.
Barthelemy H, Frappaz A, Cambazard F, Mauduit G, Rouchouse B, Kanitakis J, Souteyrand P, Claudy AL, Thivolet J. Treatment of nine cases of pemphigus vulgaris with cyclosporine. J Am Acad Dermatol. 1988 Jun;18(6):1262-6. doi: 10.1016/s0190-9622(88)70132-2. PMID: 3385040.
Schiavo AL, Puca RV, Ruocco V, Ruocco E. Adjuvant drugs in autoimmune bullous diseases, efficacy versus safety: facts and controversies. Clin Dermatol. 2010;28(3):337–343.
Downloads
Published
How to Cite
Issue
Section
